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Abstract
Background and Aims.—There are few long-term studies of health-related quality of life 
(HRQOL) in living liver donors. This study aimed to characterize donor HRQOL in the Adult to 
Adult Living Donor Liver Transplantation Study (A2ALL) up to 11 years post-donation.
Methods.—Between 2004-2013, HRQOL was assessed at evaluation, and 3 months and yearly 
post-donation in prevalent liver donors using the Short Form survey (SF-36), which provides a 
physical (PCS) and a mental component summary (MCS).
Results.—Of the 458 donors enrolled in A2ALL, 374 (82%) had SF-36 data. Mean age at 
evaluation was 38 (range 18-63), 47% were male, 93% white, and 43% had a bachelor’s degree or 
higher. MCS and PCS means were above the US population at all time points. However, at every 
time point there were some donors who reported poor scores (>1/2 standard deviation below the 
age and sex adjusted mean) (PCS: 5.3%-26.8%, MCS: 10.0%-25.0%). Predictors of poor PCS and 
MCS scores included recipient death within the two years prior to the survey and education less 
than a bachelor’s degree; poor PCS scores were also predicted by time since donation, Hispanic 
ethnicity, and at the 3-month post-donation time point.
Conclusions.—In summary, most living donors maintain above average HRQOL up to 11 years 
prospectively supporting the notion that living donation does not negatively affect HRQOL. 
However, targeted support for donors at risk for poor HRQOL may improve overall HRQOL 
outcomes for living liver donors.
Keywords
Patient Reported Outcomes; Quality of Life; Living Donor Liver Transplantation; Living Liver 
Donors; Adult to Adult Living Donor Liver Transplant Cohort Study (A2ALL)
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Living donor liver transplantation (LDLT) is a life-saving procedure for recipients with end-
stage liver disease or unresectable hepatocellular carcinoma and helps mitigate the scarcity 
of deceased donor organs [1]. The nine center Adult to Adult Living Donor Liver 
Transplantation (A2ALL) Study has demonstrated that patient and graft survival for LDLT 
recipients are excellent and in some cases supersede outcomes from deceased donor liver 
transplantation [2-5]. However, LDLT involves a healthy donor who derives no medical 
benefit from the surgery, while bearing a significant risk of morbidity and mortality [6, 7]. 
In fact, the A2ALL cohort showed that 40% of donors experience a complication, most of 
them minor (98% categorized as Clavien grade I or II); 95% resolve within the first 
postoperative year [8].
While potential LDLT donors can be informed about their short-term and long-term risks for 
morbidity and mortality based on longitudinal, multi-center clinical data, there is relatively 
little information available on the long-term effect of donation on health-related quality of 
life (HRQOL) outcomes [9, 10]. HRQOL is a multi-dimensional concept that refers to an 
individual’s physical, emotional, and social well-being as impacted by a medical condition 
or its treatment [11]. Published reports of living liver donors’ HRQOL have typically been 
single-center, cross-sectional samples with short-term follow-up periods of usually one year 
or less [9, 10, 12-32]. There remains a need for more information on the long-term effect of 
living liver donation on donor HRQOL to have a more comprehensive understanding of 
LDLT outcomes and to enhance informed consent for potential donors.
The most meaningful way to assess donor HRQOL is to ask patients directly. One strategy 
to accomplishing this is using standardized patient-reported outcomes measures. The Short-
Form health survey (SF-36) is one such measure [33, 34] with normative data from the 
general population that has been used to assess HRQOL across many different patient 
populations, including LDLT [10]. While disease-specific instruments have been used to 
characterize the HRQOL of specific populations, such as the Liver Disease Quality of Life 
survey for use in patients with chronic liver disease [35, 36], to date there is no specific 
instrument that captures the multiple HRQOL domains of importance for LDLT donors.
In the A2ALL study, living liver donor HRQOL was assessed longitudinally using the 
SF-36. We provide descriptive data for short- and long-term HRQOL for living liver donors 
captured in the multi-center A2ALL cohort. We hypothesized that there are short-term 




Data for this analysis were collected from living liver donors enrolled in the A2ALL study 
who donated between 1998 and 2010. Clinical, laboratory, hospitalization, complication and 
HRQOL data were collected between 2004 and 2013. The nine participating centers were: 
Northwestern University; Columbia University College of Physicians and Surgeons; 
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University of California, San Francisco; University of North Carolina; University of 
California, Los Angeles; Medical College of Virginia Hospitals; University of Virginia, 
Charlottesville; University of Colorado; and University of Pennsylvania. Data collection 
ceased at University of North Carolina; University of California, Los Angeles, and 
University of Virginia, Charlottesville after August 31, 2010 while the remaining six centers 
continued data collection through 2013. HRQOL surveys, which included the SF-36, were 
administered to donors enrolled in A2ALL at pre-donation evaluation, 3 months post-
donation, 1 year post-donation, and every year thereafter up to a maximum of 8 years. Some 
donors enrolled in A2ALL after their donation and were followed for a maximum of 11 
years; therefore, the cohort includes those with and without HRQOL assessments prior to 
donation (Figure 1). To maximize response rates, the SF-36 survey was administered to 
A2ALL donors in several formats (on tablet computers, via paper forms by mail or at the 
clinical center, or by web-based forms) through 2010. From 2011-2013, HRQOL data were 
collected centrally via telephone by trained interviewers at Northwestern University. To 
determine if administration mode affected HRQOL scores, we tested it as a covariate in the 
models. We found no significant effects, as all p-values were greater than 0.05 (the range of 
p-values for modes of administration were 0.24-0.60 and 0.36-0.88 for MCS and PCS 
models, respectively).
Measures and Outcomes
The SF-36 form (version 2) is a brief survey of health status consisting of 36 questions, with 
eight subscales (physical functioning, role-physical, bodily pain, general health, vitality, 
social functioning, role-emotional, and mental health). In addition, two summary measures, 
the mental component summary (MCS) and physical component summary (PCS) scores 
were calculated. The MCS and PCS scores calculated from the SF-36 survey are 
standardized on a scale from 0 to 100; the general population average is 50 with a standard 
deviation (SD) of 10. Most donors were above the national HRQOL average both pre- and 
post-donation. However, the donors who did report poor HRQOL were of interest in this 
analysis. Poor HRQOL was defined as a score that was more than 0.5 SD below the 
normative age- and sex-adjusted mean at the time of donor assessment. Half a SD is a 
typical minimally important difference in quality of life instruments [37].
For each donor, relevant recipient outcomes, such as re-transplantation and death, were 
obtained from A2ALL data, supplemented by data from the Scientific Registry of Transplant 
Recipients (SRTR) under a data use agreement. SRTR death records were only available 
through the end of 2012. The SRTR data system includes data on all donors, wait-listed 
candidates, and transplant recipients in the US, submitted by the members of the Organ 
Procurement and Transplantation Network (OPTN), and has been described elsewhere. The 
Health Resources and Services Administration (HRSA), U.S. Department of Health and 
Human Services provides oversight to the activities of the OPTN and SRTR contractors.
The study was approved by the Institutional Review Boards and Privacy Boards of the 
University of Michigan Data Coordinating Center and each of the nine participating 
transplant centers. The IRB approval number is HUM00045813; the protocol number is 
2002-0488. All subjects provided written informed consent to this study.
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Comparisons of donor characteristics between those with and without SF-36 forms were 
performed using chi-square tests or Fisher’s exact tests as appropriate.
We used a repeated measures logistic regression to model the likelihood of donors having a 
low SF-36 composite score. These models used generalized estimating equations [38] with a 
compound symmetry covariance structure for repeated measures on the same subject over 
time. Covariates considered for inclusion in the models included donor demographics (age, 
sex, race, ethnicity, education), relationship to recipient (biological, non-biological, and 
spouse), medical information (body mass index [BMI], hypertension, clinically diagnosed 
depression, use of pain medications), and lifestyle data (current smoker, former smoker, or 
nonsmoker). Variables measured over time since donation included number of 
complications prior to the time of survey, recipient outcome variables (graft failure —
defined as death or re-transplant — and/or death prior to the corresponding SF-36 survey), 
and time since donation as a continuous variable. After initial analysis we observed that 
mean HRQOL was lower at 3 months, deviating from the otherwise linear trajectory. 
Therefore, we also included an indicator variable for the 3-month time point to capture this 
deviation.
For donors with SF-36 information pre- and post-donation, logistic regression models were 
also used to test pre-donation PCS and MCS scores as predictors of post-donation HRQOL. 
Additionally, t-tests were used to assess changes in PCS and MCS scores pre-donation vs. 
scores 1 year post-donation and beyond.
Forms that were missing more than 50% of items of any SF-36 subscale were excluded from 
the analysis (N=16). Of the remaining 1,116 SF-36 forms, 1,086 (97%) were filled out 
completely. Multiple imputation using linear regression with bounds (for each ordinal item, 
lowest value – 0.5 to highest value + 0.5) was used to calculate the missing item responses 
for the 30 (3%) forms with some incomplete data. Out of 36 items, 22 forms were missing 
one item, six were missing two items, and two were missing three or four items. The 
complete and imputed responses to the 36 questions on the survey were used to calculate the 
PCS and MCS scores. For the figures that include boxplots, only the first imputation was 
used. For the models, the standard method of combining results from five imputed data sets 
was used (SAS MIANALYZE procedure). All analyses were performed using SAS version 
9.2 (SAS Institute, Inc, Cary, NC) and IVEware version 0.2 (University of Michigan, Ann 
Arbor, MI).
Results
This study included HRQOL data from 374 donors, with an average of three forms per 
donor assessment ranging from pre-donation to 11 years post-donation. These 374 donors 
represent 82% of the total donor population enrolled in A2ALL at the nine centers (N=458). 
The mean age at evaluation for donation was 38.0 ± 10.2 (range 18.2 to 62.7) years, 47% 
were male, 93% white, 12% Hispanic, and BMI ranged from 16 to 42 (Table 1). Nearly half 
the donors (43%) had an educational level reflecting a bachelor’s degree or higher. Of the 
374 donors, 354 (95%) had post-donation data. Two hundred and nineteen (59%) donors 
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enrolled prior to donation. Of those donors, 131 (60%) had pre-donation HRQOL data and 
111 (51%) had both pre- and post-donation HRQOL data (Figure 2).
Figure 3 shows boxplot distributions of PCS at each time point. At each measured time point 
the average PCS score was higher than the population norm, ranging from 50.9-56.9. The 
pre-donation mean score was 56.9 ± 4.5 (range 37.2 – 64.5);5.3% of donors had a low PCS 
score, defined as more than half a SD below the mean, adjusted for age and sex. The PCS 
scores were the lowest at three months after donation, with 27% of donors reporting low 
values, but only 6% reported poor physical well-being at 1 year post-donation. The age- and 
sex-adjusted PCS scores appear to briefly stabilize after 1 year, with the percentage of low 
values increasing slightly at later time points. Figure 4 shows boxplot distributions of MCS 
at each time point. The average MCS scores were higher than the population mean, ranging 
from 51.7-54.5. The pre-donation MCS mean was 54.3 ± 5.3 (range 39.8 – 64.5). The 
percentage of low MCS scores (more than half a SD below the mean, adjusted for age and 
sex) at the 3-month time point did not increase as seen in the PCS scores. Similar boxplots 
for each subscale are given in the supplementary information (Figures S1-S8).
Predictors of poor PCS and MCS scores
A small proportion of donors reported poor PCS and MCS scores. The significant predictors 
of poor (>0.5 SD from age-/sex-adjusted normative values) PCS and MCS scores are 
reported in Table 2. Predictors of poor PCS included recipient death within two years prior 
to reporting HRQOL data (OR=2.1, p=0.05), the 3 month time point after donation 
compared to all other time points (OR=6.4, p<0.0001), Hispanic ethnicity (OR=2.5, p=0.01), 
education less than a bachelor’s degree (OR=1.9, p=0.02), and longer time since donation as 
a continuous variable (OR=1.1 per year, p=.001). Significant predictors of a poor MCS 
score (Table 2b) were recipient death within two years prior to reporting HRQOL data 
(OR=2.9, p=0.004) and education less than a bachelor’s degree (OR=1.8, p=0.02). For both 
MCS and PCS models, some donors may not have had their recipient’s death recorded if the 
recipient’s A2ALL follow-up ended prior to 2013 and could not be supplemented by SRTR 
death data, which ended in 2012. As a sensitivity analysis, the models were re-run after 
truncating follow-up at the end of 2012 and the recipient death variable results were almost 
identical (PCS: OR=2.4, p=0.03; MCS: OR=2.6, p=0.02).
Paired Comparisons of Pre- and Post-donation Scores
In the pre- and post-donation comparison (N=111), low pre-donation MCS scores did not 
predict low post-donation MCS scores (p=0.33). Low pre-donation PCS scores slightly 
increased the likelihood of having a low post-donation PCS score (OR=1.1, p=0.04).
For donors with pre-donation and post-donation data 1 year or beyond (N=92), we tested for 
differences in MCS and PCS scores pre- and post-donation using each donor’s first and last 
annual post-donation time points. For MCS scores, no significant differences between pre- 
and post-donation scores were seen (pre-donation vs. first annual: p=0.27, vs. last annual: 
p=0.45). For PCS scores, consistent with the decreasing time trend seen in the previous 
section, significant decreases of approximately 1.7 score points were seen (pre-donation vs. 
first annual: p=0.03, vs. last annual: p=0.02).
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Comparison to patients with no SF-36 data
Comparing donors with SF-36 data to those with no SF-36 data revealed few differences 
(Table 1). Among those with SF-36 data, a greater proportion were non-Hispanic/Latino 
(88%) and had a bachelor’s degree or higher (43%) compared to those without SF-36 data 
(79% non-Hispanic/Latino, 26% with bachelor’s degree or higher; p=0.03, p=0.02, 
respectively). Those with SF-36 data were more likely to have consented pre-donation (59% 
vs. 36%, p=0.0001). Other demographic characteristics, as well as the proportion of donors 
with recipient death or graft failure during the study, did not significantly differ.
Furthermore, among donors with some SF-36 data, only recipient death increased the 
likelihood of missing forms (OR=1.6, p=0.01) (Table S1), while other demographic factors 
did not predict missingness.
Discussion
This investigation by the nine-center A2ALL study demonstrates that living liver donors 
have greater mental and physical health, as reported by the SF-36, than the general 
population and that living donor hepatectomy does not negatively affect the long-term 
HRQOL of donors.
The unique contribution of this study is that it followed the HRQOL of living donors 
prospectively from multiple centers for up to 11 years. Donors from the A2ALL study 
generally maintained emotional and physical well-being (MCS and PCS) above the 
normative population throughout the study period. However, we observed an understandable 
decrement in physical well-being in the immediate post-operative period followed by a 
return to baseline levels. We did identify a small decline in PCS scores over time, which is 
most notable in later time points and can likely be attributed to the effects of aging, a 
phenomenon also observed in the general normative population [39]. In comparison, the 
donor emotional well-being remains stable on average, and above the population norm 
throughout the donation process and after.
Our results support published findings from single-center studies that have examined the 
effect of living donation up to one year prospectively and up to 50 months cross-sectionally 
[5, 10, 12, 16, 19, 22-24, 28, 30]. These studies reported that the baseline HRQOL of living 
donors is above the normative population. The A2LL cohort, which also has higher HRQOL 
at baseline for donors compared to the normative data, may have higher HRQOL because 
the donors are more educated and of higher socioeconomic status than the normative cohort. 
Previous studies also suggest that the physical well-being deteriorates after surgery but 
returns to baseline within 6-12 months, and that mental well-being does not significantly 
change during the donation from baseline [10]. Our multi-center study demonstrates that 
living liver donation does not negatively affect HRQOL prospectively up to 11 years post-
donation. This is important information for transplant centers as they provide information to 
their potential living donors during their decision making process [2, 3, 40, 41].
Another contribution from this study is the identification of predictive factors for poor 
HRQOL after living donation. Despite the overall above average levels of HRQOL scores, 
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the A2ALL cohort identified a subgroup of donors who reported low physical or mental 
well-being, which we defined as scores 0.5 SD or more below age- and sex-adjusted 
normative values. With further investigation of this subgroup a few unexpected findings 
were observed.
One interesting group was donors who reported low HRQOL prior to donation (Total N=18; 
low PCS: 7, low MCS: 14). While there were not many donors in this category, it suggests 
that there is some variability in scores even in this generally healthy population, which did 
not prevent them from being selected as living liver donors. Interestingly, donors who 
reported low MCS scores prior to liver donation were not more likely to have lower MCS 
scores after donation, but donors with lower PCS scores prior to donation were more likely 
to report low PCS scores after donation
Another group of donors experienced HRQOL well below normative levels after 3 months 
post-donation (Total N= 102, low PCS: 41, low MCS: 77). While this group represents less 
than a third of the donors, it does suggest that there are donors who may require heightened 
surveillance post-donation. The multivariable analysis demonstrated that recent recipient 
death predicted lower donor PCS and MCS scores. A recent study identified an intermittent 
dip in HRQOL for living kidney donors whose recipient died [42]. Similar to our findings, 
those recipients mostly recovered back to baseline. While this may be intuitive, it does 
highlight the possible benefit of offering these donors bereavement counseling or other 
supportive care. It is to be noted that despite the negative effect of recipient death on donor 
HRQOL, donors did not report “donation regret” even when recipient outcomes are poor. 
Neither low MCS nor PCS scores were predicted by postoperative complications. In other 
health care settings, such as orthopedics, poor mental disposition was linked with poor 
clinical outcomes [43]. In the A2ALL cohort, such an association was not found.
Furthermore, in the A2ALL cohort, lower educational attainment (less than a bachelor’s 
degree) was predictive of low PCS and MCS scores. While studies in living liver donors 
have been disparate about the role of education on the HRQOL of donors [9, 19], our 
findings are consistent with those of the recently published RELIEVE study [44], where 
higher education had a protective effect on HRQOL. This is consistent with other studies 
showing that communication, setting of expectations, and informed consent are less 
effective when they are directed at patients with low educational attainment, as clinicians 
may not be sensitive to differences in patient literacy and numeracy in their communications 
[45, 46]. Therefore, it may be beneficial to consider ways that transplant teams can provide 
pre-donation education that is more appropriate across the full range of socioeconomic 
backgrounds and health literacy levels [47]. Such efforts can lead to improvements in 
informed consent and shared decision making, which would likely have downstream 
impacts on clinical outcomes and HRQOL [48]. These efforts may also lead to greater 
equity in access to living donor transplantation for transplant candidates and potential 
donors who have lower educational attainment and socioeconomic status.[49]
Lastly, being Hispanic predicted poor PCS scores, but it did not predict poor MCS scores. In 
other clinical settings, it has been shown that the perception of physical well-being is 
culturally dependent and may suggest that Hispanic individuals perceive their physical well-
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being differently than other ethnic groups [50]. The setting of expectations prior to living 
donation might be important to guide the post-operative experience. Also, receiving more 
culturally appropriate and congruent care before and after donation may have a direct or 
indirect impact on their HRQOL [50, 51]. One possible solution, as has been done in a 
kidney transplant setting [52], is to provide education that addresses cultural barriers in 
Spanish, by Hispanic clinicians (e.g., surgeons, hepatologists, nurses), addressing specific 
cultural barriers (e.g., position of the Catholic Church, effect on fertility).
There were several limitations to this study. First, while frequently used in HRQOL studies, 
the SF-36 is a generic instrument that does not include open-ended questions and was not 
specifically designed to assess HRQOL issues specific to the donation process. Thus, there 
may have been areas or domains of well-being that are affected by donation but were not 
adequately captured by our assessments. Efforts are underway to develop living liver donor-
specific HRQOL instruments, such as an instrument recently described by a Japanese group 
[53]. Such instruments may improve the comprehensive assessment of living donors. Also, 
A2ALL focuses on adult to adult living liver donation; our study did not include donation of 
adults to children. Finally, the data collection was incomplete; many donors did not have 
pre-donation HRQOL data due to the timing of their enrollment into A2ALL. Less than 
complete data capture occurred among enrolled donors for several reasons, including timing 
issues during clinic appointments, technical problems with computerized form 
administration, donors not returning mailed forms, and loss to follow-up. Generalizations of 
these findings are limited to living liver donor groups similar to those studied in this sample.
In summary, this investigation provides supportive data that HRQOL for living liver donors 
is generally good in the short-term and remains so in the long-term. Certain groups of 
donors, such as Hispanic donors, those with low educational attainment, and those whose 
recipients die, are at increased risk for poor perceived well-being and may benefit from 
additional or tailored support. This information will be valuable for counseling potential 
donors and for providing optimal care for those who proceed with donation.
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Study timeline and examples of donor enrollment pre-donation versus post-donation
Ladner et al. Page 13























Number of SF-36 forms by time point (N=374 donors; N=1116 forms)
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Table 1
Characteristics of donors
SF-36 Data (N=374) No SF-36 Data (N=84)
N or Mean, SD Percent or Range N or Mean, SD Percent or Range
Race
 American Indian or Alaska Native 2 0.5 0 0.0
 Asian 8 2.1 2 2.4
 Black/African American 9 2.4 3 3.6
 Native Hawaiian or Other Pacific Islander 1 0.3 1 1.2
 White 349 93.3 73 86.9
 More than One Race 5 1.3 5 6.0
Ethnicity §
 Hispanic/Latino 46 12.3 18 21.4
 Not Hispanic/Latino 328 87.7 66 78.6
Sex
 Male 174 46.5 42 50.0
 Female 200 53.5 42 50.0
Age at evaluation for donation 38.0, 10.2 18.2 – 62.7 36.6, 10.7 18.8 – 54.6
BMI at evaluation for donation 26.2, 4.0 16.4 – 42.4 26.6, 3.4 20.4 – 34.7
Relationship to recipient
 Biological 233 62.3 56 66.7
 Non-biological 97 25.9 19 22.6
 Spouse 44 11.8 9 10.7
Education attainment at evaluation for donation§
 Bachelor’s degree or higher 161 43.0 22 26.2
 Less than a bachelor’s degree 177 47.3 51 60.7
 Missing 36 9.6 11 13.1
Current smoker 37 9.9 13 15.5
Previous smoker 59 15.8 15 17.9
History of depression 29 7.8 2 2.4
Systemic hypertension 9 2.4 2 2.4
Patient reports pain drug use 70 18.7 12 14.3
 Non-prescription drug use 66 17.6 10 11.9
 Prescription drug use 7 1.9 2 2.4
Complication occurred before study end point*
 Any grade 159 42.5 36 42.9
 Grade 1 
α 57 15.2 11 13.1
 Grade 2 
α 95 25.4 23 27.4
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SF-36 Data (N=374) No SF-36 Data (N=84)
N or Mean, SD Percent or Range N or Mean, SD Percent or Range
 Grade 3 
α 2 0.5 1 1.2
SF-36 Data (N=374) No SF-36 Data (N=84)
N or Mean, SD Percent or Range N or Mean, SD Percent or Range
Complication occurred before last SF-36 time
period 147 39.3 -- --
 Grade 1 
α 51 13.6 -- --
 Grade 2 
α 90 24.1 -- --
 Grade 3 
α 2 0.5 -- --
Recipient graft failure before study end point* 109 29.1 33 39.3
 Recipient graft failure before or during last donor
SF-36 time period
† 105 28.1 -- --
Recipient death before study end point* 82 21.9 22 26.2
 Recipient death before or during last donor SF-36
time period
†










P-value < 0.05. Ethnicity (Chi-square test, p=0.03), education (Chi-square test, p=0.02), consented to A2ALL study before donation (Chi-square 
test, p=0.0001)
α
Complication grade not collected after August 31, 2010
*
Recipient graft failure/death occurred before the end of the A2ALL Cohort study
†
Recipient graft failure/death occurred before the donor’s last SF-36 form was completed
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Table 2a
Predictors of PCS more than half a SD below the mean* (N=374 donors, N=1116 SF-36 forms)
Variable OR 95% CI P-value
Hispanic/Latino (ref: not Hispanic/Latino) 2.539 1.258 5.123 0.009
Education: Bachelor's degree or higher (ref: less than a bachelor's degree or
missing) 0.531 0.308 0.915 0.023
Recipient death within two years prior to corresponding SF-36 survey 2.13 1.014 4.474 0.046
Time period is 3 months post-donation 6.382 3.599 11.315 <0.0001
Time since donation (years) 1.138 1.053 1.23 0.001
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Table 2b
Predictors of MCS more than half a SD below the mean* (N=374 donors, N=1116 SF-36 forms)
Variable OR 95% CI P-value
Education: Bachelor's degree or higher (ref: less than a bachelor's degree or
missing) 0.563 0.346 0.915 0.02
Recipient death within two years prior to corresponding SF-36 survey 2.879 1.391 5.956 0.004
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